ofloxacin has been researched along with Enteritis in 5 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Enteritis: Inflammation of any segment of the SMALL INTESTINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eradication of non-typhoid salmonellae was evaluated in a randomized, double-blinded study of 49 patients with acute enteritis after therapy with ofloxacin 400 mg once daily for 5 or 10 days." | 9.09 | Eradication of non-typhoid salmonellae in acute enteritis after therapy with ofloxacin for 5 or 10 days. ( Digranes, A; Halstensen, A; Langeland, N; Peterson, LE; Rolstad, T; Solberg, CO; Voltersvik, P, 2000) |
| "The clinical efficacy, safety and usefulness of Rokitamycin (RKM), a new macrolide antibiotic, were compared with those of Ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double blind method." | 9.07 | [Comparison of clinical efficacy of rokitamycin (RKM) and ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double-blind method. The Research Committee for the Effect of Rokitamycin, Research Group for Infectious Enteritis]. ( Machii, A; Nitta, Y; Obana, M; Ota, S; Sagara, H; Sato, J; Seo, T; Takizawa, Y; Tomizawa, I; Tsunoda, T, 1991) |
| "Eradication of non-typhoid salmonellae was evaluated in a randomized, double-blinded study of 49 patients with acute enteritis after therapy with ofloxacin 400 mg once daily for 5 or 10 days." | 5.09 | Eradication of non-typhoid salmonellae in acute enteritis after therapy with ofloxacin for 5 or 10 days. ( Digranes, A; Halstensen, A; Langeland, N; Peterson, LE; Rolstad, T; Solberg, CO; Voltersvik, P, 2000) |
| "The clinical efficacy, safety and usefulness of Rokitamycin (RKM), a new macrolide antibiotic, were compared with those of Ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double blind method." | 5.07 | [Comparison of clinical efficacy of rokitamycin (RKM) and ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double-blind method. The Research Committee for the Effect of Rokitamycin, Research Group for Infectious Enteritis]. ( Machii, A; Nitta, Y; Obana, M; Ota, S; Sagara, H; Sato, J; Seo, T; Takizawa, Y; Tomizawa, I; Tsunoda, T, 1991) |
| "We determined the minimum inhibitory concentration (MIC) of DR-3355, a newly developed quinolone-derivative antibacterial agent, against clinical isolates of various bacterial species from enteritis patients, and compared them with those of ofloxacin (OFLX), ciprofloxacin (CPFX), nalidixic acid (NA), ampicillin (ABPC), kanamycin (KM)." | 3.68 | [In vitro antimicrobial activity of DR-3355, a new quinolone antibacterial agent, against clinical isolates of enteritis-causing bacteria]. ( Horiuchi, S; Inagaki, Y; Nakaya, R; Ogawa, M; Yamamoto, N, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuyama, M | 2 |
| Kawakami, K | 1 |
| Suda, O | 1 |
| Imagawa, Y | 1 |
| Voltersvik, P | 1 |
| Halstensen, A | 1 |
| Langeland, N | 1 |
| Digranes, A | 1 |
| Peterson, LE | 1 |
| Rolstad, T | 1 |
| Solberg, CO | 1 |
| Furuhata, K | 1 |
| Oonaka, K | 1 |
| Hara, T | 1 |
| Sunakawa, K | 1 |
| Horiuchi, S | 1 |
| Inagaki, Y | 1 |
| Yamamoto, N | 1 |
| Ogawa, M | 1 |
| Nakaya, R | 1 |
| Obana, M | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Nitta, Y | 1 |
| Sagara, H | 1 |
| Seo, T | 1 |
| Sato, J | 1 |
| Tsunoda, T | 1 |
| Ota, S | 1 |
| Machii, A | 1 |
2 trials available for ofloxacin and Enteritis
| Article | Year |
|---|---|
Eradication of non-typhoid salmonellae in acute enteritis after therapy with ofloxacin for 5 or 10 days.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Enteritis; Humans; Middle Ag | 2000 |
[Comparison of clinical efficacy of rokitamycin (RKM) and ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double-blind method. The Research Committee for the Effect of Rokitamycin, Research Group for Infectious Enteritis].
Topics: Adolescent; Adult; Aged; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Double- | 1991 |
3 other studies available for ofloxacin and Enteritis
| Article | Year |
|---|---|
[In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis].
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Enteritis; Enterobacteriaceae Infections; Escheri | 1995 |
[Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Blood; Campylobacter; Electrolyt | 2000 |
[In vitro antimicrobial activity of DR-3355, a new quinolone antibacterial agent, against clinical isolates of enteritis-causing bacteria].
Topics: Bacteria; Enteritis; Microbial Sensitivity Tests; Ofloxacin | 1992 |